DS
AGRX

David Shaw’s Agile Therapeutics AGRX Stock Holding History

David Shaw’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,099
Closed -$460K – 5964
2022
Q1 		$460K Buy
1,099
+18
+2% +$11.5K ﹤0.01% 4420
2021
Q4 		$1.05M Buy
1,081
+920
+571% +$1.3M ﹤0.01% 3890
2021
Q3 		$310K Buy
161
+114
+243% +$258K ﹤0.01% 4335
2021
Q2 		$126K Sell
47
-4
-8% -$13.2K ﹤0.01% 4522
2021
Q1 		$212K Sell
51
-8
-14% -$43.2K ﹤0.01% 3836
2020
Q4 		$336K Buy
59
+32
+119% +$188K ﹤0.01% 3563
2020
Q3 		$162K Buy
+27
New +$155K ﹤0.01% 3636

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

David Shaw's AGRX Position: Q2 2022 in Review

David Shaw sold out of Agile Therapeutics (AGRX) in Q2 2022, closing a stake of 1,099 shares — an estimated $460K sold.

David Shaw first reported a position in AGRX in Q3 2020 and held it in 7 quarters. The position peaked at $1.05M in Q4 2021. 19 funds tracked by Wall St. Rank hold AGRX as of Q2 2022.

  • David Shaw reported no remaining Agile Therapeutics position as of Q2 2022 after selling out during the quarter.
  • David Shaw sold 1,099 Agile Therapeutics shares in Q2 2022, an estimated $460K.
  • David Shaw first reported a position in Agile Therapeutics in Q3 2020 and held it in 7 quarters.
  • David Shaw's Agile Therapeutics position peaked at $1.05M in Q4 2021.
  • 19 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.